What is tirzepatide?
Tirzepatide is the active ingredient in Mounjaro and Zepbound, not a brand itself. It is a once-weekly injection made by Eli Lilly, and it was the first medication in this class to act on two gut-hormone receptors, GIP and GLP-1, rather than one. The FDA first approved it in May 2022.
Because it is the molecule rather than the label, “tirzepatide” is what appears in trials and on a prescription, while the pharmacy hands you a box marked Mounjaro or Zepbound. Which box depends on what is being treated, and the two do not share indications.
Tirzepatide brand names: Mounjaro vs Zepbound
Eli Lilly sells tirzepatide as Mounjaro and Zepbound. Same molecule, same shared ladder, different approvals and different populations.
| Product | Approved for | Ages | Maintenance dose |
|---|---|---|---|
| Mounjaro | Type 2 diabetes | Adults and children 10+ | up to 15 mg, 10 mg for children |
| Zepbound | Weight management, and moderate to severe sleep apnea in adults with obesity | Adults only | 5, 10 or 15 mg; 10 or 15 mg for sleep apnea |
The gap worth knowing when comparing across molecules: no tirzepatide product carries a cardiovascular or kidney outcomes indication, while semaglutide does under both Ozempic and Wegovy. Tirzepatide’s edge is magnitude; semaglutide’s is proven outcomes.
There is no FDA-approved generic tirzepatide. Anything sold as “generic tirzepatide” or “generic Mounjaro” is compounded or counterfeit. See compounded tirzepatide below.
Is there an oral tirzepatide pill?
No. Tirzepatide is injection-only, and there is no tablet in development, because Lilly’s oral weight-management drug is a different molecule: orforglipron, now approved and sold as Foundayo since April 2026. It is a nonpeptide small molecule that acts on the GLP-1 receptor alone, not a tirzepatide tablet. The oral options in this class are the three semaglutide tablets and Foundayo.
How does tirzepatide work?
Tirzepatide acts on the receptors for two gut hormones, GLP-1 and GIP. That dual action does three things at once:
- Quiets appetite signals in the brain, so you feel full sooner and think about food less.
- Slows stomach emptying, so meals keep you satisfied longer.
- Sharpens insulin response, steadying blood sugar and how your body stores energy.
That second receptor, GIP, is what sets tirzepatide apart from single-receptor drugs like semaglutide in Ozempic and Wegovy, and it’s the leading explanation for its larger trial results. Researchers sometimes call it a “twincretin” for hitting both incretin hormones.
Receptors it activates
Dual agonist · GLP-1 + GIP
- GLP-1
Curbs appetite and triggers insulin after meals
- GIP
Amplifies the insulin response and how the body handles fat
- glucagon
Not activated
How much weight can you lose on tirzepatide?
More than any other approved medication, on current evidence. In the pivotal 72-week trial in adults with obesity and without type 2 diabetes, weight fell 15.0 percent at 5 mg, 19.5 percent at 10 mg and 20.9 percent at 15 mg, against 3.1 percent on placebo. Subtracting placebo, that is 11.9, 16.4 and 17.8 percentage points. More than 90 percent of people on 15 mg lost at least 5 percent of their body weight.
In the companion trial in people who also had type 2 diabetes, the same doses produced 12.8 and 14.7 percent against 3.2 percent on placebo. Losing less with diabetes is a consistent pattern across this class.
Here’s how the pivotal trials break down by population and dose:
| Trial | Dose | Duration | Avg. weight loss | Studied in |
|---|---|---|---|---|
| SURMOUNT-1 | 15 mg | 72 weeks | 20.9% (~48 lb) | Adults with obesity, no diabetes |
| SURMOUNT-2 | 15 mg | 72 weeks | 14.7% (~34 lb) | Adults with obesity and type 2 diabetes |
| SURPASS-2 | 15 mg | 40 weeks | 12.4% (~25 lb) | Type 2 diabetes (A1C was the primary endpoint) |
| SURMOUNT-OSA | 10–15 mg | 52 weeks | ~18–20% | Obesity with moderate-to-severe sleep apnea |
Two caveats belong beside the headline. Cross-drug comparisons here are mostly indirect, so “largest in class” rests on comparing separate trials, with one exception: the single direct obesity trial against semaglutide, covered below. And no trial figure is the drug on its own, since every arm also received structured lifestyle support and results varied widely between individuals.
What are the side effects of tirzepatide?
Mostly digestive, mostly early, and clustered around dose increases. The rates below span the two products, from Mounjaro’s diabetes-dose trials at the low end to Zepbound’s obesity trials at the high end, each shown against the placebo rate in its own trials. The span is not a ranking: different doses, different populations, different trials.
Common · usually temporary
- Nausea 12–29% vs 4–8%
- Diarrhea 12–23% vs 8–9%
- Constipation 6–17% vs 1–5%
- Vomiting 5–13% vs 2%
- Abdominal pain 5–10% vs 4–5%
- Indigestion 8–10% vs 3–4%
- Injection-site reactions 6–8% vs 2%
Serious · call your provider
- Thyroid C-cell tumors (boxed warning, from rat studies)
- Acute pancreatitis
- Acute gallbladder disease
- Severe digestive reactions
- Acute kidney injury from dehydration
- Serious allergic reactions
- Low blood sugar
- Diabetic retinopathy complications in people with a history of retinopathy
- Pulmonary aspiration during general anesthesia or deep sedation
On injection-site reactions, the number in circulation is often the wrong one. In the placebo-controlled trials they occurred in 6 to 8 percent of people against 2 percent on placebo. A separate analysis looked only at people who developed anti-drug antibodies and found 11.3 percent against 1 percent in those who did not. That figure has no placebo group and is not the general rate.
Antibodies to tirzepatide are common, in roughly half to two thirds of people depending on the trial. The labels report no identified clinically significant effect on how the drug behaves or how well it works, and separately that antibody-positive patients had more hypersensitivity and injection-site reactions. Two findings, not one. Antibody rates also cannot be compared across drugs, because the assays differ.
On the eyes, tirzepatide differs from semaglutide in a way worth stating precisely. Semaglutide’s label carries a retinopathy finding with numbers behind it. Tirzepatide’s says the drug has not been studied in proliferative retinopathy, retinopathy needing acute treatment, or macular edema. That is an absence of data, not a signal.
And one interaction that is easy to miss. Because tirzepatide slows stomach emptying, it can reduce absorption of an oral contraceptive. Both labels advise switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. Non-oral hormonal methods are not affected.
Practical management, which rests on clinical experience rather than trials of the advice itself: smaller meals, less fatty food and alcohol around injection day, and enough fluid. Persistent severe abdominal pain is not a symptom to wait out.
Tirzepatide side effects: the complete guide Every reported effect, how long each lasts, and how to manage themWho should not take tirzepatide?
Tirzepatide is a fit for most adults who qualify for it, but two conditions make it a hard no under either brand, and several more are worth flagging to your prescriber before you start.
Do not take tirzepatide if…
- You or a close family member has had medullary thyroid carcinoma (MTC)
- You have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- You've had a serious allergic reaction to tirzepatide or any ingredient in Mounjaro or Zepbound
Talk to your provider first if…
- You've had pancreatitis, gallbladder disease, or gallstones
- You have kidney disease or a history of dehydration
- You're pregnant, planning to be, or breastfeeding
- You take insulin or a sulfonylurea (higher risk of low blood sugar)
- You have type 1 diabetes, which tirzepatide is not approved for
- You have diabetic retinopathy or other existing eye disease
- You have severe gastrointestinal disease, such as gastroparesis (slowed stomach emptying)
The boxed warning drives the first contraindication: because tirzepatide caused thyroid C-cell tumors in rats, anyone with a personal or family history of medullary thyroid cancer, or with MEN 2, should not take it under either brand. Everything in the second column is not a stop sign; it is a reason to make sure your provider has the full picture first.
Tirzepatide dosage: how the schedule works
Everyone starts at 2.5 mg once weekly and steps up in 2.5 mg increments, each after at least four weeks. The ramp is what limits the digestive side effects. The Zepbound label states plainly that 2.5 mg is for treatment initiation and is not approved as a maintenance dosage, and the maximum differs by population: 15 mg for adults, but 10 mg for children aged 10 and older on Mounjaro. Per the FDA labels:
| Dose | When | Notes |
|---|---|---|
| 2.5 mg | Weeks 1–4 | For treatment initiation. The Zepbound label states it is not approved as a maintenance dosage. |
| 5 mg | From week 5 | First maintenance option for weight management |
| 7.5 mg | After at least 4 weeks | A step, in 2.5 mg increments |
| 10 mg | After at least 4 weeks | The maximum for children 10 and older on Mounjaro, and the lowest dose named for sleep apnea |
| 12.5 mg | After at least 4 weeks | Adults only |
| 15 mg | After at least 4 weeks | Maximum adult dosage under either brand |
Missed a dose? Both labels say to take it as soon as possible within 4 days (96 hours). Past that, skip it and stay on your usual day, and never double up. That window is specific to tirzepatide: Ozempic’s label says 5 days, and the daily tablets say to skip entirely.
How much does tirzepatide cost?
Price depends on which product you are prescribed and what your plan does with it. List prices run roughly $1,060 to $1,070 a month, and most people do not pay list.
- List price, either product
- ~$1,060–$1,070/mo approximate, before savings or insurance
- Zepbound self-pay, 2.5 mg
- $299/mo KwikPen and single-dose vial, same price, with a 45-day refill
- Zepbound self-pay, 5 mg
- $399/mo after the 1 December 2025 price cut
- Zepbound self-pay, 7.5 mg and above
- $449/mo covers 7.5, 10, 12.5 and 15 mg
Ways to pay less
Savings cards can lower costs for people with commercial insurance but exclude anyone on Medicare, Medicaid, VA or TRICARE coverage. Medicare’s temporary GLP-1 Bridge covers Zepbound’s KwikPen only, not the single-dose pen or vial, and does not cover Mounjaro at all, since the Bridge is weight-management only.
Full breakdowns live on the brand pages: Mounjaro cost for diabetes coverage, Zepbound cost for weight-management coverage and the self-pay ladder.
What tirzepatide costs, product by product List prices, the self-pay ladder, savings-card fine print and coverageIs compounded tirzepatide legal and safe?
The honest version is that this route has largely closed, though not as cleanly as either side claims.
Mass compounding rested on tirzepatide being on the FDA’s shortage list, and that shortage was declared resolved in December 2024, which removed the basis for it. FDA’s actual standard has three separate parts: whether a compounded product is essentially a copy of an approved drug, whether a prescriber has determined a significant difference for an individual patient (a route that exists under 503A with no equivalent under 503B), and the shortage list as an independent supply gate. A proposal to bar GLP-1s from the 503B bulk-substances list was still pending rather than final as of August 2026.
We cover this landscape informationally, meaning where it stands legally, how to tell a licensed pharmacy from a grey-market seller, and what the risks are. We do not recommend any compounded seller.
One practical hazard worth naming: compounded product is sometimes dosed in units rather than milligrams, which has produced measurement and concentration errors. If you are handed a syringe rather than a pen, confirm the exact unit-to-milligram conversion with the prescriber or pharmacy before drawing a dose.
Tirzepatide vs other GLP-1 drugs
The short version: tirzepatide produced the largest weight loss of any approved medication, semaglutide has the longer track record plus cardiovascular outcome indications and a tablet option, and retatrutide is not approved.
| Attribute | Tirzepatide | Semaglutide | Retatrutide |
|---|---|---|---|
| Active ingredient | tirzepatide | semaglutide | retatrutide |
| Sold as | Mounjaro · Zepbound | Ozempic · Wegovy · Rybelsus | – |
| Receptors targeted | Dual: GIP · GLP-1 | Single: GLP-1 | Triple: GIP · GLP-1 · glucagon |
| How it’s taken | Weekly injection | Weekly injection · Daily pill | – |
| FDA-approved for | Type 2 diabetes · Weight management & sleep apnea | Type 2 diabetes · Weight management | Not yet approved |
| Avg. weight loss in trials | ~21% | ~15% | ~24% |
| List price (before insurance) | ~$1,060–$1,070/mo | ~$935–$1,349/mo | – |
| Maker | Eli Lilly | Novo Nordisk | Eli Lilly |
Tirzepatide vs Semaglutide
Tirzepatide acts on two receptors to semaglutide's one and produced more weight loss in the one direct trial, but semaglutide carries cardiovascular outcome indications that no tirzepatide product has.
Tirzepatide vs Retatrutide
Retatrutide adds a third receptor and posted even larger trial numbers, but it remains investigational, not approved and not available by prescription.
How to get tirzepatide
Tirzepatide is prescription-only, dispensed as Mounjaro or Zepbound. Three legitimate paths:
1
Through your doctor
Any prescriber can write tirzepatide. Bring your insurance details, since coverage often requires prior authorization, and your doctor's office handles that paperwork.
2
Through telehealth
Licensed online clinics evaluate you remotely and, if appropriate, prescribe tirzepatide or a tirzepatide-based program, usually within a few days.
3
Pharmacy + savings
Prescriptions fill at regular pharmacies or the maker's direct program. Check the manufacturer savings card before paying list price.
Telehealth options we've reviewed
All provider reviewsNo legitimate tirzepatide without a prescription. Sellers offering it with no medical review are operating outside the law, and counterfeit pens are common. Stick to licensed providers and pharmacies. Important safety information
We're independent: we don't sell medication. Some links may earn us a commission at no cost to you; it never affects what we recommend. Prices change often, so always confirm with the provider.
Tirzepatide myths and misconceptions
As the newest and strongest drug in the class, tirzepatide collects a specific set of mix-ups: with semaglutide, between its own two brands, and around compounding. Here is what is actually true behind the five claims we hear most.
Myth Tirzepatide is a GLP-1 drug.
It is a dual agonist, acting on both the GIP and GLP-1 receptors. That second receptor is the leading explanation for its larger trial results, though what GIP adds on its own is not fully settled.
Myth Tirzepatide is just Ozempic or semaglutide under another name.
It's a different molecule. Semaglutide (Ozempic, Wegovy) targets one receptor; tirzepatide targets two, and beat semaglutide in their head-to-head trial.
Myth Mounjaro and Zepbound are different drugs.
Same molecule and the same ladder, but different approvals. Mounjaro covers type 2 diabetes in adults and children 10 and up. Zepbound covers weight management and sleep apnea, in adults only.
Myth Compounded tirzepatide is identical to the brand.
It isn't FDA-verified for dose, purity, or quality, and those can vary between sellers. Compounded copies sit in a contested legal grey zone.
Myth There's a tirzepatide pill.
No. Tirzepatide is injection-only. Lilly's oral drug orforglipron, approved as Foundayo, is a different molecule rather than a tablet version of tirzepatide.